Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Austin, Texas, June 4th, 2026, FinanceWire

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

• The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level.
• Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis.
• The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.

Neurological disorders are increasingly recognized as one of the world’s most significant healthcare challenges as aging populations and rising disease prevalence place growing pressure on healthcare systems globally. According to the World Health Organization, neurological conditions are now the leading cause of illness and disability worldwide, affecting more than one-third of the global population. Despite advances in treatment, many currently approved therapies for neurodegenerative diseases primarily focus on symptom management rather than directly addressing underlying neurodegeneration, leaving substantial unmet medical needs across the sector. Current drugs for multiple sclerosis do not address loss of mobility and function which remains an unmet patient need today.

Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing a novel, new…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Contact